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Pharmacokinetic modelingWe evaluated in vivo the integrity of brain cholinergic pathways in Multiple System Atrophy (MSA) and the re-
lationship between cholinergic dysfunction and motor disturbances, by measuring the vesicular acetylcholine
transporter (VAChT) expression using Single Photon Emission Computed Tomography (SPECT) and [123I]-
iodobenzovesamicol ([123I]-IBVM).
Methods: Nine patients with probable MSA and 12 healthy volunteers underwent a dynamic [123I]-IBVM SPECT–
CT scan and a magnetic resonance imaging (MRI) scan. All patients were examinedwith the UniﬁedMSA Rating
Scale (UMSARS; subscale I = activities of daily living (ADL), II = motor and IV = disability). CT andMRI images
were used to register the dynamic SPECT image to the Montreal Neurological Institute brain template, which in-
cludes the regions of interest (ROI) of striatum and Ch1 (medial septum nucleus-hippocampus), Ch4 (nucleus
basalis of Meynert-cortex) and Ch5–Ch6 (pedunculopontine and laterodorsal tegmental nuclei-thalamus) cho-
linergic pathways. For each ROI, pharmacokinetic modeling of regional time activity curves led to the calculation
of [123I]-IBVM to VAChT binding potential (BPND) value, proportional to VAChT expression.
Results: When compared to controls, BPND values for MSA in Ch5–Ch6 were signiﬁcantly decreased in both the
pedunculopontine–laterodorsal nuclei and the thalamus (p = 0.004 and p = 0.006, respectively). Additionally,
thalamus BPND values were correlated with UMSARS ADL (p = 0.006), motor (p = 0.002) and disability (p =
0.02) sub-scores. UMSARS motor subscale items 13 (postural instability) and 14 (gait) were also correlated
with thalamus BPND values (p = 0.04).
Conclusion: Ch5–Ch6 are the most affected cholinergic pathways inMSA at both cell bodies and thalamic cholin-
ergic terminals. These results underscore the relevant role of [123I]-IBVM SPECT for improving our understanding
of the pathophysiology in MSA.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. aire, Hôpital du Haut-Lévêque,
+33 5 57 65 64 08; fax: +33
azere).
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Multiple System Atrophy (MSA) is an adult-onset progressive
neurodegenerative disease characterized by a variable combination
of parkinsonism, cerebellar ataxia, autonomic failure and pyramidal
signs (Stefanova et al., 2009; Watanabe et al., 2002).
As in Parkinson's disease (PD), the loss of nigro-striatal dopamine
neurons causes the onset of parkinsonian motor signs in MSA. However,
in contrast to PD, MSA patients show a poor response to dopaminergic
drugs, suggesting additional involvement of non-dopaminergic systems.
In this view, post-mortem studies have revealed a loss of mesopontine
cholinergic neurons (Schmeichel et al., 2008). Moreover, in vivo imagingnse. 
Table 1
Patient demographics and UMSARS scores.
Patient
no.
Type Age
(years)
Gender Disease
duration
(years)
UMSARS
ADL
UMSARS
motor
UMSARS
disability
1 MSA-P 70 F 3 21 21 2
2 MSA-P 65 M 10 25 40 3
3 MSA-P 72 M 4 17 20 1
4 MSA-C 59 M 6 18 20 2
5 MSA-C 56 M 5 26 23 1
6 MSA-C 62 M 7 16 25 2
7 MSA-C 59 M 5 40 45 4
8 MSA-C 61 M 2 21 22 2
9 MSA-C 63 M 5 31 29 3
213J. Mazere et al. / NeuroImage: Clinical 3 (2013) 212–217studies have shown a decrease of acetylcholinesterase (AChE) activity
in both cortical and subcortical structures (Gilman et al., 2010) and a
decrease of the vesicular acetylcholine transporter (VAChT) in the thal-
amus (Gilman et al., 2003). Subcortical AChE activity is further correlat-
edwith gait disturbances (Gilman et al., 2010) and VAChT expression in
the thalamus has an inverse correlation with the severity of obstructive
sleep apnea (Gilman et al., 2003). The thalamus is the main projection
area of cholinergic neurons originating from the pedunculopontine
(PPT) and laterodorsal tegmental nuclei. The results of previous studies
therefore suggest an important role of dysfunction of the Ch5–Ch6
(ponto-thalamic) cholinergic pathways in the pathophysiology of
MSA. However, although the PPT–LDT are thought to play a pivotal
role in the genesis of motor disorders and the control of the sleep–
wake cycle and attention (Jenkinson et al., 2009), the integrity of cholin-
ergic neurons in these nuclei has never been studied in vivo inMSA. This
is partly due to technical problems, namely the small size of the PPT and
LDT. In order to overpass this problem, we recently proposed a new
method of in vivo quantiﬁcation of VAChT expression in Single Photon
Emission Computed Tomography (SPECT) imaging, using anatomical
image to brain atlas non-rigid registration (Lamare et al., 2013).
We extend here the ﬁndings of previous in vivo studies in MSA
(Gilman et al., 2010, 2003) by exploring the integrity of the Ch5–Ch6
cholinergic pathways by SPECT with [123I]-iodobenzovesamicol ([123I]-
IBVM), a selective radioligand of the VAChT (Kuhl et al., 1994; Mazere
et al., 2012). Cell bodies in the PPT and terminals in the thalamusFig. 1. Representative SPECT images of a healthy participant and patient with MSA. MNI MR im
injection for healthy participant (HP, row B) and patient with MSA (row C). For each row, thre
striatum, thalamus and PPT–LDT regions has been extracted from SPECT images by calculating
activity concentration (i.e. non speciﬁc binding)) and is presented overlaid (B, C) with the MN
labels the pedunculopontine and laterodorsal tegmental nuclei. For patient with MSA, speciﬁcwere assessed, aswell as the relationship between cholinergic denerva-
tion andmotor disturbances.We also explored the Ch4 (nucleus basalis
of Meynert-cortical (Wevers, 2011)) and Ch1 (septo-hippocampal
(Wevers, 2011)) cholinergic pathways at both levels, cell bodies
(basal forebrain cholinergic nuclei) and terminals, i.e. cortical regions
for the Ch4 and hippocampus for the Ch1.
2. Materials and methods
2.1. Subjects
Twenty one subjects were included after written informed consent:
9 patientswith “probable”MSA (8men, 1woman)were recruited at the
French Reference Centre for MSA (University Hospital of Bordeaux) and
12 healthy volunteers (3men, 9women)without neurological and neu-
ropsychiatric disorders. The diagnosis of MSA was made according to
consensus criteria (Gilman et al., 1999). Six patients had probable
MSA-C and three had probable MSA-P at the moment of the imaging
protocol. All patients were evaluated with the Uniﬁed MSA Rating
Scale (UMSARS; subscale I = activities of daily living (ADL), II =
motor and IV = disability). The diagnosis of MSA was conﬁrmed post-
mortem in three patients who came to necropsy after the end of the
study.
2.2. Standard protocol approvals, registrations and patient consent
The study was initiated after protocol approval by the institutional
Human Ethics Committee and radioactive drug approval by theNational
Health Product Safety Agency. Before providingwritten consent, all par-
ticipantswere presentedwith the basic design of the study andwere in-
formed that they could withdraw from the investigation at anytime.
2.3. Radiochemistry
[123I]-IBVM was prepared and controlled as previously described
(Mazere et al., 2008). Brieﬂy, after radio-iodination, [123I]-IBVMwas pu-
riﬁed by High Pressure Liquid Chromatography and Sep-PackC18 classic
cartridge (Waters; Milford, MA) and ﬁltered, leading to 10 ml of sterile
solution of [123I]-IBVM. Prior to injection, the solution was assessed toaging template (row A) and representative example of SPECT images acquired at 7 h after
e images, from left to right, are transverse, coronal and sagittal views. Speciﬁc binding in
difference (region of interest activity concentration (i.e. total binding)— reference region
I T1 MR imaging template. Solid white arrows label the thalamus and dotted white arrow
binding is visually lower in thalamus than for healthy participant.
Fig. 2. Box plots showing BPND values calculated in Ch1–Ch4, Ch5–Ch6 and striatal cholinergic interneurons of healthy subjects and MSA patients. The line within the box marks the me-
dian, boundaries above and below indicates the 75th and 25th percentile respectively. Whiskers above and below the box indicates the 90th and 10th percentiles. Abbreviations: BFCS:
basal forebrain cholinergic system; HPC: hippocampus; PPT–LDT: pedunculopontine and laterodorsal tegmental nuclei. *p ≤ 0.006.
214 J. Mazere et al. / NeuroImage: Clinical 3 (2013) 212–217be pyrogen-free using the Endosafe-PTS portable test system (Charles
River Laboratories, Wilmington, MA).
2.4. Scanning protocol
2.4.1. Anatomic MR imaging
For anatomical localization and partial volume effect (PVE) correc-
tion of the SPECT data, subjects underwent a three-dimensional T1 MR
imaging sequence (repetition time (TR)/echo time (TE), 7.1/3.5 ms;
ﬂip angle, 8°; ﬁeld of view, 256 × 256 mm to cover the whole brain
yielding 228 slices and slice thickness of 1 mm; voxel size, 1 mm3)
using a 1.5-T MR imaging system (Philips, Best, The Netherlands).
2.4.2. SPECT–CT imaging
SPECT imaging was performed on a SPECT/CT SYMBIA T2 camera
(Siemens; Erlangen, Germany) equipped with low energy thin section
collimators. The participants were given 400 mg of potassium perchlo-
rate orally 30 min before and 24 h after imaging. After a mean intrave-
nous injection of 267.02 ± 33.91 MBq of [123I]-IBVM, the dynamic
SPECT imageswere acquired over 7 h at ﬁve different times: ﬁve frames
of 6 min at injection time and two 15-min frames at 1 h, 2.5 h, 4.5 h and
7 h after injection (64 projections with a matrix of 64 × 64 over 360°).Table 2
Correlation between imaging (BPND values) and clinical data.
Imaging data Thalamus BPND PPT–LDT BPND
Correlation coefﬁcent p Correlation coefﬁcent p
Age 0.041 0.92 0.510 0.16
Disease duration −0.300 0.43 0.493 0.18
UMSARS ADL −0.823 0.006 −0.0319 0.94
UMSARS motor
Total −0.881 0.002 0.243 0.53
Item 13 (instability) −0.684 0.04 0.522 0.15
Item 14 (gait) −0.684 0.04 0.213 0.58
UMSARS disability −0.762 0.02 0.0665 0.87
PPT–LDT = Pedunculopontine and laterodorsal tegmental nuclei; Bold = p b 0.05.Between each of the ﬁve acquisitions, the participants were allowed to
rest outside of the gantry.
SPECT images were reconstructed on a 64 × 64 matrix by using a
ﬂash three-dimensional iterative reconstruction (four iterations, eight
subsets) and a voxel size of 6.8 × 6.8 × 6.8 mm3. With low energy
high resolution collimators, the reconstructed spatial resolution of the
images was ≤5.8 mm (center), ≤5.0 mm (radial) and ≤4.1 mm (tan-
gential). Attenuation correction was performed using the CT image.
All reconstructed images were post-processed, including decay cor-
rection, normalization for frame duration and frame merging. All the
frames were rigidly registered together and with the CT image, to en-
sure the patient's brain was in the exact same position in all the images
during the creation of the dynamic SPECT dataset.2.5. SPECT data registration to theMontreal Neurological Institute template
The anatomical images, CT andMRIwere used to register the dynam-
ic [123I]-IBVM SPECT image to the Montreal Neurological Institute (MNI)
template and the associated set of brain regions of interests (ROIs). The
acquisition and processing protocol involved three main steps: 1) The
participants' CT andMR images were coregistered by using a rigid regis-
tration. Because these two images corresponded to the same participant,
a rigid model (three translations and three rotations) was sufﬁcient. The
rigid transformation parameters were subsequently applied to the dy-
namic SPECT data to ensure the coregistration with the patients' MR im-
ages. 2) The participants'MR imageswere segmented to extract the skull
and cerebrospinal ﬂuid and to only preserve the voxels corresponding to
thewhite and gray tissues of the brain. This processwas necessary to ob-
tain an MR image with similar anatomic information as the MNI tem-
plate from which images of the skull and the cerebrospinal ﬂuid were
removed. 3) Finally, the MR craniumless scan was spatially coregistered
with theMNI T1-weighted brain template by using an elastic registration
algorithm (FSL software, Oxford, United Kingdom). The transformations
resulting from 1) and 3) were subsequently applied to the four-
dimensional SPECT dataset that had previously been aligned with the
participants' MR images, providing a four-dimensional SPECT image reg-
istered to the MNI template.
Fig. 3. Scatter plotwith regression line of UMSARS sub-scores and thalamic binding poten-
tials. UMSARS I (A), UMSARS II (B) andUMSARS IV (C) sub-scores strongly correlatedwith
thalamic binding potentials.
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2.6.1. Partial volume effect correction of the normalized dynamic
SPECT dataset
For partial volume effect correction of the four-dimensional
SPECT image registered to the MNI template, extracerebral tissue
(i.e. cerebrospinal ﬂuid plus cranium) was eliminated on MR images
of each participant by using an SPM5 (Wellcome Department of Imag-
ing Neuroscience, London, England) automatic two-segment (brain tis-
sue and cerebrospinal ﬂuid) MR segmentation method (Giovacchini
et al., 2004). The resulting mask, shown to be sufﬁcient in studies of
neurodegenerative diseases (Meltzer et al., 1999), was applied voxel-
by-voxel to the four-dimensional SPECT image, resulting in unchanged
voxels in the MR-derived white and gray matter and voxels set to 0 in
the cerebrospinal ﬂuid and cranium regions (Giovacchini et al., 2004).Finally, for each participant, an MNI-registered and partial volume
effect-corrected dynamic SPECT data was obtained and transferred to
PMOD software (version 3.1, PMOD Technologies, Zurich, Switzerland;
http://www.pmod.com) for derivation of regional time–activity curves.
2.6.2. Time–activity curve calculation
A template in theMNI spacewas created on the basis of the anatomic
automatic labeling brain segmentation (Tzourio-Mazoyer et al., 2002).
The template was built by merging some of the anatomic automatic la-
beling brain segmentation regions to deﬁne ROIs of striatum for pharma-
cokinetic modeling, and the three main anatomic cholinergic pathways:
Ch1, includingmedial septum and hippocampus; Ch4, including nucleus
basalis of Meynert (NbM); frontal, parietal and temporal cortices; and
Ch5-Ch6, including pedunculopontine (PPT) and laterodorsal (LDT) nu-
clei and thalamus. We created volumes of interest surrounding each nu-
cleus in the MNI space. The NbM, PPT–LDT and medial septum volumes
were respectively 2 × 153, 2 × 93 and 2 × 93 voxels, respectively. Final-
ly, the NbM andmedial septumweremerged together, providing the re-
gion of “the basal forebrain cholinergic nuclei”.
The PMODsoftwarewas used to apply this template to each frame of
the registered and partial volume effect-corrected dynamic SPECT data
to obtain average-decay corrected regional activities, which were plot-
ted against time to get regional time–activity curves.
2.6.3. Pharmacokinetic model
In a previous study (Barret et al., 2008),multilinear analysis by using
multilinear reference tissue model 2 was shown to give the best corre-
lation between results by using the occipital cortex as a reference region
and results from invasive blood-sampling analysis (Kuhl et al., 1994).
Therefore, themultilinear reference tissuemodel 2methodwas consid-
ered to be themethod of choice for non-invasive quantiﬁcation of [123I]-
IBVM data. A two-step approach used with multilinear reference tissue
model 2, combining calculation of the reference region-to-plasma k'2
and multilinear regression analysis (Barret et al., 2008), for each ROI,
led to the calculation of the non-displaceable binding potential (BPND)
value, a parameter whose value is proportional to the density of recep-
tor sites, in this case, VAChT binding sites. The occipital cortex was cho-
sen as a reference region because, in this area, post-mortem choline
acetyltransferase levels (Araujo et al., 1988) – an enzyme distributed
in the same way as VAChT in the human brain (Erickson et al., 1994;
Kuhl et al., 1996) – and in vivo speciﬁc binding of [123I]IBVM (Kuhl
et al., 1994; Mazere et al., 2012) were both shown to be very low.
In our study, we applied the same method and calculated [123I]-
IBVM to VAChT BPND values for each participant and each ROI.
2.7. Statistical analysis
Mann–WhitneyU testswere used to test differences in BPND values in
each ROI between control participants and patients with MSA. The re-
sults of the present study included corrections formultiple comparisons:
with eight regions examined, a conservative multiple comparisons by
using Bonferroni adjustment required a signiﬁcance level of p b 0.006.
Correlations between BPND values in each ROI and age, disease dura-
tion and clinical data (UMSARS I, II and IV subscores) were assessed by
using Pearson correlations. Statistical analyses were performed using
STATISTICA software version 9 (Statsoft; Tulsa, OK, USA: http://www.
statsoft.com).
3. Results
3.1. Subject characteristics
MSA patients (63.0 ± 5.2 years) were signiﬁcantly younger than
healthy subjects (69.8 ± 4.7 years; p b 0.01). The male–female ratio
was higher in patients with MSA than in controls. Mean disease dura-
tion was 5.2 ± 2.3 years (Table 1). Mean UMSARS ADL scores were
216 J. Mazere et al. / NeuroImage: Clinical 3 (2013) 212–21723.9 ± 7.7, mean UMSARS motor scores were 27.2 ± 9.2 and mean
UMSARS disability scores were 2.2 ± 1.0.
3.2. Cholinergic pathways integrity assessment
In Ch5–Ch6, BPND values for MSA were signiﬁcantly decreased in
both the PPT–LDT and the thalamus (p = 0.004 and p = 0.006, respec-
tively) comparatively to control participants (Figs. 1 and 2). On the con-
trary, in Ch4 and Ch1, no signiﬁcant differences in BPND values were
observed between patientswithMSA and control participantswhatever
the level, cell bodies and terminals (Fig. 2).
No correlation was found between BPND values and age irrespective
of the ROI and the group, suggesting that age differences between
groups did not affect BPND values.
3.3. Correlation between BPND and clinical markers
Thalamus BPND values were correlated with UMSARS ADL (p =
0.006), motor (p = 0.002) and disability (p = 0.02) sub-scores, while
no correlation was found with disease duration (Table 2, see also
Fig. 3). UMSARS motor subscale items 13 (postural instability) and 14
(gait) were also correlated with thalamus BPND values (p = 0.04). No
correlation was found between PPT–LDT BPND values, disease duration
and clinical data.
4. Discussion
The main result of the present study is the signiﬁcant alteration of
the Ch5–Ch6 pathways in MSA with a relative preservation of Ch1 and
Ch4 pathways. We further found a signiﬁcant correlation between
BPND values in the thalamus and UMSARS ADL, motor and disability
scores suggesting progressive cholinergic denervation with increasing
disease burden.
The observation that [123I]-IBVM binding is only reduced in the PPT–
LDT nuclei and their connecting projection area, the thalamus, supports
the hypothesis of a speciﬁc ponto-thalamic cholinergic degeneration in
MSA. This result is consistent with a post-mortem analysis revealing a
loss of PPT–LDT cholinergic neurons in MSA patients (Schmeichel
et al., 2008) and anatomical data showing that PPT–LDT cholinergic
neurons are mainly connected to the thalamus (Schmeichel et al.,
2008). From a functional point of view, cholinergic PPT–LDT damage is
consistent with clinical observations, as these cholinergic nuclei are
implicated in the coordination of gait (Jenkinson et al., 2009), the latter
being severely impaired in MSA. Although we did not ﬁnd a signiﬁcant
correlation between BPND values in the PPT–LDT and UMSARS
subscores, a strong argument for the involvement of the Ch5–Ch6 cho-
linergic network inmotor features inMSA is provided by the signiﬁcant
correlation between thalamic BPND values and UMSARS motor scores
including item scores for postural instability and gait. The absence of a
correlation between PPT–LDT BPND values and clinical markers could
result from the existence of different cholinergic sub-populations in
these nuclei (Mesulam et al., 1989) and limited power of the study for
such an analysis given the small sample size.
The absence of cortical cholinergic denervation in both Ch4 and Ch1
cholinergic pathways is in agreement with recent ﬁndings in MSA pa-
tients showing normal in vivo brain AChE activity (Hirano et al., 2008),
however not reported in another study (Gilman et al., 2010).
Quantiﬁcation of cholinergic neurons in small structures like the
PPT–LDT is questionable when using a low resolution imaging tech-
nique such as SPECT. Nevertheless, several lines of evidence support
its technical feasibility. First, quantiﬁcation of the weak signal observed
requires adapted image analysis methods. In this regard, modeling
based BPND calculations have proven to be preferable methods. There-
fore, given that our quantiﬁcation relies on a fully automated method,
the SPECT resolution can be improved if quantitative analysis relies on
an exact identiﬁcation of the different brain regions. This is whyreliability of SPECT toMRI registration is crucial. Thus, we chose an elas-
tic based registration algorithm,which is able to account for local defor-
mation, particularly if the subject's MRI is affected by cerebral atrophy
(Lamare et al., 2013). Secondly, the low SPECT resolution could be a lim-
itation when studying adjacent and very small cholinergic structures.
However, this problem should not be relevant for small cholinergic
structures not closely surrounded by other adjacent cholinergic struc-
tures, such as the PPT, which is, with the LDT, the only cholinergic struc-
ture located in the pons area (Jenkinson et al., 2009).
The signiﬁcant age and gender differences between patient and con-
trol groupmerit consideration as a study limitation, although there was
no direct correlation of BPND values and age.
5. Conclusion
Our results strongly support the hypothesis that Ch5–Ch6 are
the most affected cholinergic pathways in MSA, with signiﬁcant
neuronal loss affecting both PPT–LDT cell bodies and thalamic cho-
linergic terminals. These results underscore the relevant role of
[123I]-IBVM SPECT for studying the integrity of cholinergic path-
ways and for improving our understanding of the pathophysiology
in MSA. Given the parallel alteration of the dopaminergic systems
in this pathology, it would be interesting to explore subsequently
in vivo in MSA patients both cholinergic and dopaminergic neuro-
transmission, for a better understanding of the relationship be-
tween motor disturbances and neurotransmitter changes.
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